From Medscape Oncology

Genitourinary Cancers Symposium (GUCS) 2020

February 13 - 15, 2020; San Francisco, California

February 13 - 15, 2020 San Francisco, California

GUCS 2020 Unprecedented Response Rate in Advanced Bladder Cancer The combination of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial cancer was called 'very promising' by an expert not involved with an early phase trial.
Medscape Medical News, February 19, 2020
GUCS 2020 'Incredible' Results With Kidney Cancer Agent With Nobel Ties Once thought to be "undruggable," a target in renal cell carcinoma now has a drug aimed at it, and initial results from a small clinical trial are promising.
Medscape Medical News, February 17, 2020
GUCS 2020 A Failed Strategy for an Effective Bladder Cancer Drug When the number of doses of BCG for high-grade non-muscle invasive bladder cancer was cut, outcomes were inferior in a randomized clinical trial.
Medscape Medical News, February 17, 2020

GUCS 2020 'Incredible' Results With Kidney Cancer Agent With Nobel Ties
Medscape Medical News, February 17, 2020
GUCS 2020 A Failed Strategy for an Effective Bladder Cancer Drug
Medscape Medical News, February 17, 2020
GUCS 2020 A Rare QoL Study That Could Change Practice
Medscape Medical News, February 14, 2020